Catalent

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Catalent, Inc.
Public company
Traded asNYSECTLT
S&P 400 Component
ISINUS1488061029 Edit this on Wikidata
IndustryPharmaceuticals
PredecessorCardinal Health PTS
Founded2007
HeadquartersSomerset, New Jersey, US
Number of locations
39 (2019)[1]
Key people
John Chiminski
(Chair, CEO),
Alessandro Maselli
(President, COO),
Wetteny Joseph[2]
(Executive Vice President, CFO)
ServicesDrug pre-formulation, formulation, analytical testing, clinical and commercial manufacturing, clinical packaging and supply chain, regulatory consulting
RevenueUS$2,518.0 million (2019)[1]
US $273.9 million (2019)[1]
US $137.4 million (2019)[1]
Number of employees
12,000 (2019)[1]
Websitewww.catalent.com

Catalent, Inc. (Catalent Pharma Solutions) is a multinational corporation headquartered in Somerset, New Jersey, US. It is a global provider of delivery technologies, development, drug manufacturing, biologics, gene therapies and consumer health products. It employs more than 12,000 people, including approximately 2,400 scientists and technicians. In fiscal year 2019, it generated over $2.5 billion in annual revenue.[3]

Catalent was formed in April 2007 when affiliates of the Blackstone Group L.P. acquired the core of the pharmaceutical technologies and services (PTS) segment of Cardinal Health, Inc.[4] Cardinal Health created PTS through a series of acquisitions starting with R.P. Scherer Corporation in 1998.[5]

In 2014, Catalent became a public company and is listed on the New York Stock Exchange (NYSECTLT).

History[edit]

Before 2007[edit]

In 1996, Cardinal Health acquired PCI (Headquarters: Philadelphia, Pennsylvania).[6] PCI (Packaging Coordinators Inc.) is a pharmaceutical contract packing service for commercial and clinical packaging.[7]

In 1998, Cardinal Health acquired R.P. Scherer Corporation (Headquarters: Troy, Michigan).[8] Robert Pauli Scherer founded the R.P. Scherer Corporation to commercialize his innovation of softgel encapsulation using the rotary die production process.[9] The following year, in 1999, Cardinal Health acquired Automatic Liquid Packaging, Inc. (Headquarters: Woodstock, Ill.),[6] whose Blow-Fill-Seal Technology allowed Cardinal to enter the sterile product market.[9]

In 2002, Cardinal Health acquired Magellan Laboratories Inc., a company that specialized in product development expertise.[6] In 2003, Cardinal Health acquired Gala Biotech (Headquarters: Madison, Wisconsin).[6] In the same year, Cardinal Health also acquired Intercare Group PLC, broadening its global capabilities in Europe.[6]

From 2004 to 2006, Cardinal Health further expanded its reach in biotechnology and pharmaceutical markets through multiple acquisitions.[6]

Formation of Catalent in 2007[edit]

In 2007, the pharmaceutical technologies and services segment of Cardinal Health was purchased by Blackstone Group and re-branded as Catalent Pharma Solutions.[4]

After 2007 and initial public offering[edit]

In 2012, Catalent acquired Aptuit, a clinical supply company. As part of the deal, Catalent gained three sites in the US, two in the UK, and one in Singapore.[10] Catalent also acquired all remaining shares for the R.P Scherer site in Eberbach, Germany.[8][11][12] In 2013, Catalent continued the global expansion of its Softgel capabilities through a joint venture with Zhejiang Jaing Yuan Tang Biotechnology Co, a China-based company, and Relthy Laboratories in Brazil.[13]

Catalent announced its initial public offering in July 2014. After raising more than $870 million, Catalent became a publicly traded company on the New York Stock Exchange (NYSE).[14] The company priced its 42.5 million shares of common stock at $20.50 apiece, with a market capitalization of $2.4 billion. The shares began trading on the NYSE in July 31, 2014, under the ticker symbol CTLT.[14]

In November 2014, Catalent announced it had acquired Micron Technologies, a provider of particle size engineering technologies.[15][16] The acquisition allowed Catalent to expand its portfolio of drug delivery technologies.[15]

In 2016, Catalent licensed the anti-body drug conjugate (ADC) to Triphase Accelerator to help with oncology development,[17] and bought Pharmatek Laboratories to add spray drying to their manufacturing capabilities.[18] In September 2017, Catalent agreed to acquire Cook Pharmica for $950 million, allowing Catalent to expand their biologic manufacturing.[19] In July 2018, Catalent extended their work with Juniper Pharmaceuticals with a $133 million deal.[20]

Alessandro Maselli was appointed as president and chief operating officer in 2019, a newly created position within Catalent.[21] In March, 2019, Catalent invested more than $27 million to commercialize Zydis Ultra. The investment includes new Zydis lines; changes to one of their facilities in Swindon, UK; and a custom suite for commercial equipment.[22] Later in 2019, Catalent partnered with GB Sciences to develop a cannabinoid-derived medicine for Parkinson's disease utilizing the Zydis delivery method.[23]

In April 2019, Catalent agreed to acquire Paragon Bioservices Inc for $1.2 billion to expand its gene-therapy manufacturing capabilities.[24] The deal was completed in May 2019 and included an agreement with Sarepta Therapeutics, a gene therapy manufacturer.[25] As of October 2019, Paragon's employee numbers have almost doubled since the April acquisition.[26]

In June 2019, Catalent acquired Bristol-Myers' European launch pad to expand its global CDMO.[27]

In January 2020, Catalent purchased a manufacturing facility located in Anagni, Italy, from Bristol-Myers Squibb, to manufacture and package biologic and oral solid dose products for multiple companies.[28] In February 2020, Catalent agreed to acquire MaSTherCell, a Belgian gene and cell therapy manufacturer, for $315 million. The acquisition allows Catalent to expand into cell therapy development.[29][30]

In 2020, Catalent partnered with multiple drugmakers, including Pfizer, Johnson & Johnson,[31] AstraZeneca,[32] and Moderna[33] to provide manufacturing, vial filling and packaging capabilities for COVID-19 vaccine candidates.[34][35] Catalent also partnered with ViralClear to manufacture a COVID-19 vaccine candidate at Catalent's St. Petersburg facility.[36]

Financials[edit]

Annual Financial Table[1]
# 2016 2017 2018 2019
Sales/Revenue 1.85B 2.08B 2.46B 2.52B
Total Current Assets 3.09B 2.45B 4.53B 6.18B
Net Operating Cash Flow 155.3M 299.5M 374.5M 247.7M

References[edit]

  1. ^ a b c d e f "Catalent, Inc. 2019 Annual Report" (PDF). Retrieved 28 January 2020.
  2. ^ "Wetteny Joseph Believes in You". Retrieved 30 July 2020.
  3. ^ "Catalent, inc. 2019 Annual Report" (PDF). Catalent Investors. Retrieved 27 November 2019.
  4. ^ a b "Cardinal Health Completes Sale of Pharmaceutical Technologies and Services Segment to The Blackstone Group". Dublin, Ohio: Blackstone Group. 10 April 2007.
  5. ^ "Cardinal Health Agrees to Acquire Scherer for $2.07 Billion in Stock". The Wall Street Journal. 19 May 1998. Retrieved 2 December 2019.
  6. ^ a b c d e f "Cardinal Health's timeline -- CardinalHealth.com". CardinalHealth.com. Archived from the original on 11 April 2015. Retrieved 7 April 2015.
  7. ^ "PCI leads the market in healthcare packaging solutions". PCI Services. Retrieved 7 April 2015.
  8. ^ a b "Catalent completes acquisition of R P Scherer Eberbach". Manufacturing Chemist. Manufacturing Chemist. 1 March 2012. Retrieved 7 April 2015.
  9. ^ a b Kuehn, Steven (6 October 2014). "Container Innovation's Prairie Home". Pharmaceutical Manufacturing. Retrieved 7 April 2015.
  10. ^ "Catalent completes Aptuit deal". BioPharma-reporter.com. 20 February 2012. Retrieved 7 April 2015.
  11. ^ Wasserman, Robert (8 September 2016). "2 big companies and 1 small one to target in the pharma/biotech space". TheStreet. Retrieved 9 July 2019.
  12. ^ "Gelita and R.P. Scherer End 60 Year Joint Venture". .foodingredientsfirst.com/. Retrieved 9 July 2019.
  13. ^ Stanton, Dan (10 October 2013). "Catalent's Brazilian acquisition supports global softgel strategy". inPharma-technologist.com. Retrieved 7 April 2015.
  14. ^ a b "Catalent Issues Initial Public Offering" (8). PharmTech.com. Pharmaceutical Technology Sourcing and Management. 4 August 2014. Retrieved 7 April 2015.
  15. ^ a b "Catalent Acquires Micron Technologies, Adds Particle Engineering Capabilities to Portfolio". Pharmtech.
  16. ^ "Catalent Pharma Solutions acquires Micron Technologies - 2014-11-13". Crunchbase. Retrieved 25 June 2019.
  17. ^ "Catalent out-licenses ADC to Triphase". BioPharma Dive. Retrieved 4 October 2019.
  18. ^ "Catalent Buys Pharmatek and Lands Spray Drying Technology". Pharmaceutical Investing News. 14 September 2016.
  19. ^ "Catalent targets biologics with Cook Pharmica acquisition". Pharmaceutical Commerce. 19 September 2017. Retrieved 21 November 2019.
  20. ^ "Catalent extends expansion with $133M deal for Juniper Pharmaceuticals". FiercePharma. Retrieved 16 August 2019.
  21. ^ "Catalent Names Alessandro Maselli President and Chief Operating Officer". finance.yahoo.com. Retrieved 19 February 2019.
  22. ^ "Catalent Invests in Zydis Ultra Commercialization". pharmtech.com.
  23. ^ "Wellness products take off in the growing recreational cannabis market". Marijuana Business Magazine. 1 October 2019. Retrieved 9 December 2019.
  24. ^ Hopkins, Kimberly Chin and Jared S. "Catalent to Buy Paragon Bioservices for $1.2 Billion". WSJ. Retrieved 1 November 2019.
  25. ^ "Catalent's new prize, Paragon, adding capacity to make Sarepta gene therapies". FiercePharma. Retrieved 26 November 2019.
  26. ^ "Paragon growing quickly toward 1,000 employees after Catalent acquisition". Baltimore Business Journal. 17 October 2019. Retrieved 23 December 2019.
  27. ^ "'It's a growth play': Catalent acquires Bristol-Myers' European launch pad, expanding global CDMO ops". Endpoints News. Retrieved 18 October 2019.
  28. ^ "Bristol-Myers offloads manufacturing plant to Catalent". Outsourcing-Pharma. 13 January 2020.
  29. ^ "Catalent laying out $315M to snatch another gene therapy CDMO". FiercePharma. Retrieved 3 February 2020.
  30. ^ "Catalent adds to regenerative therapy portfolio with $315m acquisition". Manufacturing Chemist. 3 February 2020.
  31. ^ "Pfizer to outsource some drug production, focus on coronavirus vaccine". CNBC. 9 May 2020. Retrieved 16 June 2020.
  32. ^ "AstraZeneca Picks Catalent for Packaging, Supplying Potential COVID-19 Vaccine". The New York Times. 15 June 2020. Retrieved 16 June 2020.
  33. ^ "Moderna Is the Latest Coronavirus Vaccine Partner for Catalent". Barrons. Retrieved 7 July 2020.
  34. ^ "'Vaccine Nationalism': A New Dynamic in the Race to Quash Coronavirus". Wall Street Journal. 27 May 2020. Retrieved 16 June 2020.
  35. ^ "Vaccine makers face biggest medical manufacturing challenge in history". Reuters. 25 June 2020.
  36. ^ "Manufacturer to help develop potential Covid treatment at St. Pete facility". Tampa Bay Business Journal. Retrieved 17 July 2020.